Why is MDGL down?
Down 8% on Nov 3, and still 12% under its Nov 2 close.
- Its Nov 3 results:
−2Long-term trend
Down 8% on Nov 3, and still 12% under its Nov 2 close.
−2Long-term trend
Follow MDGL's trial news. Pro members can get an alert when Madrigal Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Free cash flow -$169M on $1.4B of sales |
| Latest filing | 8-K, Nov 3 |
Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -5.4% on average, higher 1 of 4 times.
$961M in cash
General Counsel Shannon T. Kelley sold 1,077 shares on Nov 6, under a planned sale. 22 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
MDGL is #94 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 94 |
Share count against a year before: MDGL +2.6%, XENE +26%, VKTX +5.1%.
Expected to report Thu Feb 18, before the open (in 89 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Third-quarter 2026 net revenues were $431.3 million, an increase of 50% compared to $287.3 million in the comparable prior year period, driven by increased demand for Rezdiffra in the U.S. in 2026.”
MDGL's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in cost of sales was primarily driven by higher royalties payable to Roche as a result of increased net sales of Rezdiffra in 2026.”
From its results filing (SEC filing · Nov 3)
Its share count grew 9.4% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +4.2% | -8.1% | +0.4% |
| Jul 30, 2026 | -7.6% | -9.8% | -6.0% |
| May 6, 2026 | +5.7% | +7.4% | +1.6% |
Sales grew in two of the last three years, to $958M in 2025. It lost money in each of the four years.
RSI 26.2, MACD below signal, below both averages. Not scored.
One insider bought $35M across 5 filings, and 2 insiders sold $1.7M across 11 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: MDGL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
“The development and commercialization of drugs in MASH is highly competitive.”
MDGL scores 1 today, which Breakaway calls Below Average. It is #94 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 8% on Nov 3, and still 12% under its Nov 2 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MDGL scores 1 today, which Breakaway calls Below Average (0 to 5). That is #94 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MDGL's 1.
One insider bought $35M across 5 filings, and 2 insiders sold $1.7M across 11 filings, in the last 6 months. The newest is Baker Bros. Advisors LP, Director, who bought $23.1M on Nov 6. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.